From target therapy to miRNA therapeutics of human multiple myeloma: Theoretical and technological issues in the evolving scenario

Current Drug Targets

Volumn 14, Issue 10, 2013, Pages 1144-1149

  Rossi, Marco ^a   Amodio, Nicola ^a   Di Martino, Maria Teresa ^a   Caracciolo, Daniele ^a   Tagliaferri, Pierosandro ^a   Tassone, Pierfrancesco ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Temple University   (United States)

Author keywords

Bone disease; MicroRNA; miRNA; Multiple myeloma; Non coding RNA; Target therapy

Indexed keywords

BORTEZOMIB; CATHEPSIN K; CYCLIN DEPENDENT KINASE 6; EXPORTIN 5; GELATINASE A; GELATINASE B; INTERLEUKIN 6; LET 7A; MICRORNA; MICRORNA 106B; MICRORNA 15; MICRORNA 155; MICRORNA 16; MICRORNA 181A; MICRORNA 181B; MICRORNA 192; MICRORNA 194; MICRORNA 215; MICRORNA 221; MICRORNA 222; MICRORNA 29B; MICRORNA 32; MICRORNA 34A; MICRORNA 382; NOTCH1 RECEPTOR; PROTEIN P53; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STAT3 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; BIOGENESIS; BONE DISEASE; CELL PROLIFERATION; GENE EXPRESSION PROFILING; HUMAN; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; NORTHERN BLOTTING; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; BONE MARROW; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA;

EID: 84881349597     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/13894501113149990186     Document Type: Review

References (63)

1. O'Dwyer ME, Druker BJ. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. Curr Cancer Drug Targets 2001; 1(1): 49-57.
2. Younes H, Leleu X, Hatjiharissi E, et al. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 2007; 13(13): 3771-5.
3. Ghobrial IM, Weller E, Vij R, et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011; 12(3): 263-72.
4. Ghobrial IM, Munshi NC, Harris BN, et al. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol 2011; 86(7): 573-8.
5. Jakubowiak AJ, Richardson PG, Zimmerman T, et al. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/ refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol 2012; 158(4): 472-80.
6. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128(4): 683-92.
7. Smith EM, Boyd K, Davies FE. The potential role of epigenetic therapy in multiple myeloma. Br J Haematol 2010; 148(5): 702-13.
8. Cea M, Cagnetta A, Gobbi M, et al. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des 2013; 19(4): 734-44.
9. Gomase VS, Parundekar AN. microRNA: human disease and development. Int J Bioinform Res Appl 2009; 5(5): 479-500.
10. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10(10): 704-14.
11. Tagliaferri P, Rossi M, Di Martino MT, et al. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012; 12(7): 838-46.
12. Denli AM, Tops BB, Plasterk RH, et al. Processing of primary microRNAs by the Microprocessor complex. Nature 2004; 432(7014): 231-5.
13. Gregory RI, Yan KP, Amuthan G, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004; 432(7014): 235-40.
14. Lund E, Guttinger S, Calado A, et al. Nuclear export of microRNA precursors. Science 2004; 303(5654): 95-8.
15. Haase AD, Jaskiewicz L, Zhang H, et al. TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. EMBO Rep 2005; 6(10): 961-7.
16. Eulalio A, Huntzinger E, Nishihara T, et al. Deadenylation is a widespread effect of miRNA regulation. RNA 2009; 15(1): 21-32.
17. Starega-Roslan J, Krol J, Koscianska E, et al. Structural basis of microRNA length variety. Nucleic Acids Res 2011; 39(1): 257-68.
18. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008; 26(3): 317-25.
19. Lindow M, Gorodkin J. Principles and limitations of computational microRNA gene and target finding. DNA Cell Biol 2007; 26(5): 339-51.
20. Rajewsky N. microRNA target predictions in animals. Nat Genet. 2006; 38 Suppl: S8-13.
21. Sethupathy P, Megraw M, Hatzigeorgiou AG. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 2006; 3(11): 881-6.
22. Thomas M, Lieberman J, Lal A. Desperately seeking microRNA targets. Nat Struct Mol Biol 2010; 17(10): 1169-74.
23. Lee D, Shin C. MicroRNA-target interactions: new insights from genome-wide approaches. Ann N Y Acad Sci 2012; 1271: 118-28.
24. Tassone P, Tagliaferri P. Editorial: New approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta). Curr Cancer Drug Targets 2012; 12(7): 741-2.
25. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008; 105(35): 12885-90.
26. Zhou Y, Chen L, Barlogie B, et al. High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 2010; 107(17): 7904-9.
27. Lionetti M, Biasiolo M, Agnelli L, et al. Identification of microRNA expression patterns and definition of a microRNA/ mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009; 114(25): e20-6.
28. Wu P, Agnelli L, Walker BA, et al. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol 2013; 162(3); 348-59.
29. Lionetti M, Musto P, Di Martino MT, et al. Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia. Clin Cancer Res 2013; 19(12): 3130-42.
30. Roccaro AM, Sacco A, Thompson B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009; 113(26): 6669-80.
31. Lionetti M, Agnelli L, Lombardi L, et al. MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2012; 12(7): 823-37.
32. Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53- inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18(4): 367-81.
33. Loffler D, Brocke-Heidrich K, Pfeifer G, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3- mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007; 110(4): 1330-3.
34. Sarasquete ME, Gutierrez NC, Misiewicz-Krzeminska I, et al. Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica 2011; 96(3): 468-71.
35. Chiosea S, Jelezcova E, Chandran U, et al. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res 2007; 67(5): 2345-50.
36. Merritt WM, Lin YG, Han LY, et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359(25): 2641-50.
37. Duchaine TF, Slack FJ. RNA interference and micro RNA-oriented therapy in cancer: rationales, promises, and challenges. Curr Oncol 2009; 16(4): 61-6.
38. Kumar R, Singh SK, Koshkin AA, et al. The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio- LNA. Bioorg Med Chem Lett 1998; 8(16): 2219-22.
39. Braasch DA, Corey DR. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol 2001; 8(1): 1-7.
40. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438(7068): 685-9.
41. Zhang Y, Roccaro AM, Rombaoa C, et al. LNA-mediated antimiR- 155 silencing in low-grade B-cell lymphomas. Blood 2012; 120(8): 1678-86.
42. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV Infection by Targeting MicroRNA. N Engl J Med 2013; 368(18): 1685-94.
43. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003; 17(4): 438-42.
44. Wiggins JF, Ruffino L, Kelnar K, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70(14): 5923-30.
45. Trang P, Medina PP, Wiggins JF, et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 2010; 29(11): 1580-7.
46. Roccaro AM, Sacco A, Maiso P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013; 123(4): 1542-55.
47. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10(12): 1470-6.
48. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9(6): 654-9.
49. Di Martino MT, Leone E, Amodio N, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012; 18(22): 6260-70.
50. Calimeri T, Battista E, Conforti F, et al. A unique threedimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011; 25(4): 707-11.
51. Amodio N, Leotta M, Bellizzi D, et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 2012; 3(10): 1246-58.
52. Amodio N, Di Martino MT, Foresta U et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop of the the transcription factor Sp1. Cell Death Dis 2012; 3: e436.
53. Tassone P, Neri P, Burger R, et al. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets 2012; 12(7): 814-22.
54. Leone E, Morelli E, Di Martino MT, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013; 19(8): 2096-106.
55. Di Martino MT, Gulla A, Cantafio ME, et al. In vitro and in vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma. Oncotarget 2013; 4(2): 242-55.
56. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27(3): 165-76.
57. Mellis DJ, Itzstein C, Helfrich MH, et al. The skeleton: a multifunctional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption. J Endocrinol 2011; 211(2): 131-43.
58. Dhodapkar KM, Barbuto S, Matthews P, et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008; 112(7): 2878-85.
59. Noonan K, Marchionni L, Anderson J, et al. A novel role of IL-17- producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010; 116(18): 3554-63.
60. Hideshima T, Chauhan D, Schlossman R, et al. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20(33): 4519-27.
61. Rossi M, Pitari MR, Amodio N, et al. miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol 2012.
62. Zhang J, Zhao H, Chen J, et al. Interferon-beta-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. FEBS Lett 2012; 586(19): 3255-62.
63. Kapinas K, Delany AM. MicroRNA biogenesis and regulation of bone remodeling. Arthritis Res Ther 2011; 13(3): 220.